Efficacy of HUEXC030 in Subjects With Pulmonary Tuberculosis

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Clinical Phase

PHASE2/PHASE3

Total Enrollment

557 participants

Study Classification

INTERVENTIONAL

Study Start Date

2012-12-06

Study Completion Date

2019-01-09

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

Assess the Efficacy of HUEXC030 as Add-on Excipient to Eradicate Anti-Tuberculosis Drugs Induced Hepatic Injury ( ATDH ) in Subjects with Pulmonary Tuberculosis

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Short Course Regimen in Low Risk Active Tuberculosis- a Multicenter, Randomized, Active-controlled, Trial

NCT06727864

Pulmonary Tuberculosis

RECRUITING PHASE3

Evaluation of the Efficacy and Safety of a 4-month Daily Regimen (2HZPM/2HPM) for Treatment of Pulmonary TB

NCT04856644

Tuberculosis, Pulmonary

ACTIVE_NOT_RECRUITING PHASE3

Efficacy and Safety of Intravenous Treatment of Tuberculosis

NCT04150367

Tuberculosis, Pulmonary

TERMINATED

Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Ex-vivo Antitubercular Activity of PBTZ169 Formulation

NCT03423030

Tuberculosis Tuberculosis, Pulmonary

COMPLETED PHASE1

Evaluating the Early Bactericidal Activity, Safety and Tolerability of Nebulised RESP301 in Adults With Tuberculosis

NCT06041919

Rifampicin Susceptible Pulmonary Tuberculosis

TERMINATED PHASE2

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

The study drug is Isoniazid formulated with HUEXC030 as excipient for eradicating ATDH, whereas the reference control is Isoniazid formulated with inactive excipient. Subjects who fulfill all the entry criteria and have written informed consent will be enrolled to the study. Eligible subjects will be randomized in a 1:1 ratio to receive study drug or reference control drug. Subjects will be genotyped according to a selected panel of single nucleotide polymorphisms (SNPs) and categorized into high risk or low risk groups for occurring ATDH via a specific haplotype consists of CYP2E1 and NAT2 SNPs. Based on an extensive study result during 2007 to 2011,the estimated frequency for patients bearing high risk genotypes in Taiwanese population is around 25%. Approximately 352 subjects will be enrolled for genotype screening in order to recruit 88 high risk subjects for each of 44 subjects in the intervention and control arms.

Subjects who are stratified as high risk groups will be administered the test drug or reference control drugs oral daily for 6 months or until treatment completion, i.e. bacteriologically confirmed negative of active M. tuberculosis. Subjects who are of low risk genotype will be removed from study after 8 weeks of study treatment, then return to conventional TB medication under the care of their investigator for at least one follow-up visit at 4 weeks after the End of Study.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Pulmonary Tuberculosis

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

PARALLEL

Primary Study Purpose

TREATMENT

Blinding Strategy

TRIPLE

Participants Caregivers Investigators

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Isoniazid with HUEXC030 and RZE

Subjects who are genotyped as high risk group will be receiving 2 months of intensive treatment comprised of 4 drugs (Isoniazid with HUEXC030 \[H\], rifampin \[R\], pyrazinamide \[Z\] and ethambutol \[E\]), followed by 4 months of continual chemotherapy consist of Isoniazid, Rifampin (2HRZE/4HR regimen). Subjects who are of low risk genotype will be removed from study after 8 weeks of study treatment, then return to conventional TB medication at least one follow-up visit at 4 weeks after the end of study treatment visit.

Dosage is as below:

Isoniazid with Isoniazid(H):300mg/600mg daily, rifampin \[R\]: 450\~600mg daily, pyrazinamide \[Z\]; 1000\~2000mg daily and ethambutol \[E\]: 800-1600mg daily)

Group Type EXPERIMENTAL

Isoniazid with HUEXC030 and RZE

Intervention Type DRUG

Subjects will receive oral study drug daily in accordance with the following regimen, that is, INH, RMP, PZA, and EMB for the first 2 months followed by INH, RMP and EMB (if medically indicated) daily for 4 additional months

Isoniazid

Subjects who are genotyped as high risk group will be receiving 2 months of intensive treatment comprised of 4 drugs (Isoniazid \[H\], rifampin \[R\], pyrazinamide \[Z\] and ethambutol \[E\]), followed by 4 months of continual chemotherapy consist of Isoniazid, Rifampin (2HRZE/4HR regimen). Subjects who are of low risk genotype will be removed from study after 8 weeks of study treatment, then return to conventional TB medication at least one follow-up visit at 4 weeks after the end of study treatment visit.

Dosage is as below:

Isoniazid (H):300mg daily, rifampin \[R\]: 450\~600mg daily, pyrazinamide \[Z\]; 1000\~2000mg daily and ethambutol \[E\]: 800-1600mg daily)

Group Type OTHER

HRZE

Intervention Type DRUG

the same as experimental group,without the excipient of HUEXC030 only

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Isoniazid with HUEXC030 and RZE

Subjects will receive oral study drug daily in accordance with the following regimen, that is, INH, RMP, PZA, and EMB for the first 2 months followed by INH, RMP and EMB (if medically indicated) daily for 4 additional months

Intervention Type DRUG

HRZE

the same as experimental group,without the excipient of HUEXC030 only

Intervention Type DRUG

Other Intervention Names

Discover alternative or legacy names that may be used to describe the listed interventions across different sources.

INH with HUEXC030, RMP, PZA and EMB INH, RMP, PZA and EMB

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

1. A definite case of pulmonary TB
2. Patient who is exposed to 3 or less doses of first-line anti-TB drug treatment for current disease.
3. Age ≥ 20 years
4. Have well documented baseline liver function tests that indicates patient's adequate liver function for enrollment to study.

i. AST and ALT \< 3x ULN ii. total serum bilirubin \< 2.0 mg/dL

Exclusion Criteria

1. Have alcoholic liver disease or habitual alcohol consumption \> 30 g/day for more than one year
2. Previously diagnosed of:

i. extra-pulmonary TB without concomitant lung invasion ii. HIV iii. liver malignancy iv. liver cirrhosis v. any other systemic diseases that may cause liver dysfunction
3. Documented history of serious allergic reaction or resistance to isoniazid, rifampicin, ethambutol, pyrazinamide, sugar alcohols or any structurally related compounds
4. Subjects who will be using the following therapies after TB treatment starts:

i. antiretroviral agents ii. oral corticosteroids
5. Subjects are pregnant or lactating
6. Subjects with child-bearing potential who are not committed to take reliable contraception during the participation of the study and at least 4 weeks after the end of the study treatment
7. Subjects with any other serious disease considered by the investigator not in the condition to enter into the trial

Minimum Eligible Age

20 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No